MNHS researchers awarded $53million in NHMRC Investigator Grants
Monash Medicine, Nursing and Health Sciences researchers have been successful in obtaining 29 National Health and Medical Research Council (NHMRC) Investigator Grants valued at over $53 million, the highest result ever awarded to the faculty since the grants were introduced.
The competitive Investigator Grants provide the highest-performing researchers at all career stages with consolidated funding for their salary and a significant research support package to provide the flexibility to pursue important new research directions as they arise, adjust their resources accordingly, and form collaborations as needed, rather than being restricted to the scope of a specific research project.
Projects combating antimicrobial resistance, assisting infants transition at birth, engaging older people to improve medication management and reducing opioid mortality and harm were among those funded.
Deputy Dean of Research Professor James Whisstock said the large amount of successful grant outcomes was a fantastic achievement by our leading researchers. “We’re very pleased to see our researchers’ efforts recognised and supported by the NHMRC. Our warmest congratulations and best wishes to all recipients,” he said
The MNHS projects awarded are:
Researcher | Funding | School/Institute | Project |
$2,953,040 | Biomedicine Discovery Institute | Combating antimicrobial resistance: From bedside to bench and therapeutics | |
$2,753,040 | Biomedicine Discovery Institute | Harnessing the immune system to treat viral infections and their complications | |
$1,953,040 | School of Clinical Sciences | Assisting infants transition at birth | |
$2,897,165 | Central Clinical School | Harnessing microbes and metabolites to combat respiratory diseases | |
$2,897,165 | School of Nursing and Midwifery | ENgaginG older people Across transitions of care to improve medication manaGEment (The ENGAGE Project) | |
$2,897,165 | Central Clinical School | A new model for improved syphilis management and control | |
$2,297,165 | School of Psychological Sciences | Cognitive neuroscience of human decision-making in health and disorder | |
$2,697,165 | Central Clinical School | Transforming epilepsy outcomes through innovative technologies | |
$2,717,732 | Hudson Institute of Medical Research | Targeting the cancer epigenome for therapy | |
$2,769,655 | School of Public Health and Preventive Medicine | Harnessing research translation science to drive ‘the right care’ | |
$2,169,655 | Biomedicine Discovery Institute | Protecting the ovary from damage to optimise fertility and endocrine health in women | |
$2,769,655 | School of Public Health and Preventive Medicine | The application of genomic technology to public health & prevention | |
$2,897,165 | Eastern Health Clinical School | Transforming approaches to reduce opioid mortality and related harm | |
$2,769,655 | Central Clinical School | Multiple sclerosis in childbearing women: Clinical management, consequences and biological mechanisms | |
$793,095 | School of Clinical Sciences | Preventing pre-eclampsia to improve outcomes for mothers and babies | |
$1,293,095 | School of Clinical Sciences | Improving outcomes for patients with central nervous system lymphoma through precision medicine | |
$1,586,190 | Central Clinical School | The cerebellum-striatum axis in progressive movement disorders | |
$1,586,190 | School of Clinical Sciences | Changing the way we use diet in gut disorders: Generating mechanistic knowledge and clinical evidence to inform integrated management | |
$1,586,190 | Central Clinical School | Accelerating progress toward hepatitis C elimination as a public health threat | |
$1,188,491 | Central Clinical School | Understanding and targeting the epigenome in blood cancers | |
$1,586,190 | School of Clinical Sciences | Creatine: The next frontier in nutritional supplements to reduce perinatal brain injury | |
$1,586,190 | Australian Regenerative Medicine Institute | Investigating the transcriptional repair program during muscle reconstruction | |
$643,126 | Biomedicine Discovery Institute | Lipid antigen mediators of T cell responses against Mycobacterium tuberculosis infection | |
$662,040 | School of Public Health and Preventive Medicine | Identifying barriers to public trust and participation in genomic screening programmes, and strategies to address barriers | |
$662,040 | School of Psychological Sciences | A digital biomarker for circadian medicine: timing is key | |
$662,040 | Biomedicine Discovery Institute | Harnessing ticks' tricks to develop therapies for inflammatory diseases | |
$445,775 | School of Public Health and Preventive Medicine | Diabetes and cardiometabolic risk and prevention in pregnancy and beyond | |
$662,040 | School of Public Health and Preventive Medicine | Designing adaptive strategies to drive tuberculosis towards elimination | |
$662,040 | Central Clinical School | Preventing sudden unexpected death in epilepsy: Identifying predictive biomarkers and advancing automated seizure detection for real-time interventions |
For more information about the Investigator Grants, visit the NHMRC website.
About Monash University
Monash University is Australia’s largest university with more than 80,000 students. In the 60 years since its foundation, it has developed a reputation for world-leading high-impact research, quality teaching, and inspiring innovation.
With four campuses in Australia and a presence in Malaysia, China, India, Indonesia and Italy, it is one of the most internationalised Australian universities.
As a leading international medical research university with the largest medical faculty in Australia and integration with leading Australian teaching hospitals, we consistently rank in the top 50 universities worldwide for clinical, pre-clinical and health sciences.
For more news, visit Medicine, Nursing and Health Sciences or Monash University.
MEDIA ENQUIRIES